Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Non-Current Liabilities (2016 - 2025)

Intellia Therapeutics has reported Total Non-Current Liabilities over the past 9 years, most recently at $170.7 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 46.49% to $170.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $170.7 million through Dec 2025, down 46.49% year-over-year, with the annual reading at $170.7 million for FY2025, 46.49% down from the prior year.
  • Total Non-Current Liabilities was $170.7 million for Q4 2025 at Intellia Therapeutics, down from $319.1 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $319.1 million in Q4 2024 and troughed at $170.7 million in Q4 2025.
  • The 5-year median for Total Non-Current Liabilities is $238.1 million (2022), against an average of $236.8 million.
  • Year-over-year, Total Non-Current Liabilities grew 27.21% in 2024 and then tumbled 46.49% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $254.2 million in 2021, then increased by 2.47% to $260.5 million in 2022, then decreased by 3.72% to $250.8 million in 2023, then rose by 27.21% to $319.1 million in 2024, then tumbled by 46.49% to $170.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Total Non-Current Liabilities are $170.7 million (Q4 2025), $319.1 million (Q4 2024), and $250.8 million (Q4 2023).